Navigation Links
Encorium Reports Second Quarter 2009 Financial Results
Date:8/24/2009

eek stockholder approval to liquidate and dissolve. Any decision to liquidate and dissolve the Company may occur at any point during or before the first quarter of 2010. It is unclear whether there would be funds available for distribution to our stockholders in these instances.

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process.

This press release contains forward-looking statements identified by words such as "estimate," "project," "expect," "intend," "believe," "anticipate" and similar expressions regarding the potential sale Encorium Oy and our expectations regarding the effects of such transactions. Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to: (i) the timing of the
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
4. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
5. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
6. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
7. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
8. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
9. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. QMed, Inc. Reports July Medicare SNP Enrollments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled ... 2pm EST (11am PST), “Natural Language Processing: Converting Raw ... technology can turn raw, heterogeneous data into actionable knowledge ... online webinar will last approximately one hour. , Synopsis: ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Reportlinker.com announces that a new market research report ... Global Biotechnology Reagents Industry ... the worldwide markets for Biotechnology Reagents in US$ ... Reagents, DNA Sequencing/Synthesis Reagents, Electrophoresis Reagents, Flow Cytometry ...
... licensed within the next 4 years, as manufacturers are ... candidates in collaboration with health authorities and developing countries ... licensure, a team of leading scientists said. ... for regulatory review of dengue vaccines, while plans are ...
... from the University at Buffalo could lead to new solutions ... from drinking water. To the naked eye, both water ... are measured by the nanometer, a unit of length about ... , But at the microscopic level, the two actually differ ...
Cached Biology Technology:Reportlinker Adds Global Biotechnology Reagents Industry 2Capacity of developing country NRAs key to accelerated introduction of upcoming dengue vaccines 2Capacity of developing country NRAs key to accelerated introduction of upcoming dengue vaccines 3A nano-solution to global water problem: Nanomembranes could filter bacteria 2
(Date:7/10/2014)... ant Anoplolepis gracilipes is ranked amongst the top ... ecological impacts on islands. A new study published in the ... assesses the effects and dangers of the introduction of the ... palm forest of the Valle de Mai, a UNESCO World ... Valle de Mai is a unique ecosystem containing many endemic ...
(Date:7/9/2014)... Philadelphia, PA, July 10, 2014 Inflammatory diseases ... same patient, complicating treatment because a medication effective ... such example is the anti-arthritic medication dexamethasone, which ... disease. A study in the August issue of ... the effects of a new class of anti-arthritic ...
(Date:7/9/2014)... Bacteria found in the bladders of healthy women ... form of incontinence, according to researchers from Loyola ... These findings, published July 9, 2014, in the ... , suggest that bacterial communities may play a ... incontinence (UUI) is a common, yet poorly understood, ...
Breaking Biology News(10 mins):Invasion of yellow crazy ant in a Seychelles UNESCO palm forest: Threats and solutions 2New class of anti-arthritis drugs effectively treats multiple inflammatory diseases 2
... know - are drawing up gold particles from the earth via ... from CSIRO made the discovery and have published their findings in ... a hydraulic pump its roots extend tens of metres into ... gold is likely to be toxic to the plant, it,s moved ...
... , Oct. 23, 2013 Increasing awareness ... commercial biometrics market. While historically the adoption of ... recent years have witnessed considerable demand for applications ... finance. Iris and face recognition algorithms have undergone ...
... SALT LAKE CITYFor people with a family history of ... to 10 percent of colorectal cancers could be missed ... is the third most common cancer in the United ... population-based study to date, researchers from Huntsman Cancer Institute ...
Cached Biology News:There's gold in them thar trees 2Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 2Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 3Frost & Sullivan: Global Commercial Biometrics Market to Grow Considerably as Awareness Increases 4Colon cancer screening guidelines may miss 10 percent of colon cancers 2
... 20 years of expertise in the field ... offers the most powerful systems on the ... 40 000 in-microplate tests requiring incubation and ... different modules (such as worktable shaker incubators, ...
... or Isolated Sequence) siRNA Test System is ... evaluation of a potential of any DNA ... for RNA interference (RNAi). Current computer-based RNAi ... the probability of selected sequence to be ...
... pre-validated SNP sequencing services ... within 93 genes including ... more than 80 tyrosine ... were developed and validated ...
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
Biology Products: